Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278112 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TSHRCASP1 | |
| SCHEMBL11151929 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL22214435 | 0.72 | ALDH1A1 (0.56) | ALDH1A1TSHRCASP1 | |
| SCHEMBL6036829 | 0.70 | ALDH1A1 (0.54) | ALDH1A1TSHRCASP1 | |
| SCHEMBL10967365 | 0.70 | ALDH1A1 (0.54) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL14572071 | 0.70 | ALDH1A1 (0.54) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL11723260 | 0.69 | ALDH1A1 (0.52) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL11470284 | 0.69 | ALDH1A1 (0.52) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL19386340 | 0.68 | ALDH1A1 (0.50) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11729516 | 0.68 | ALDH1A1 (0.50) | ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-113956333-B | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-113956333-A | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-01-21 | — | — | CN | disclosed |
| US-20210024525-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-9411226-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| EP-1926770-B1 | COLOR FAST POLYURETHANES | CIBA HOLDING INC (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20080119581-A1 | Material for Metallic-Pattern Formation, Crosslinking Monomer, and Method of Forming Metallic Pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-5410047-A | A 2-hydroxyamino-4,6-substituted triazine as light stabilizers for polymers; radiation resistance, oxidation resistance, discoloration inhibition | CIBA-GEIGY CORPORATION (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0413665-B1 | Polymer stabilizers containing both hindered amine and nitrone moieties | CIBA GEIGY AG (CH) | 1995-04-05 | — | — | EP | disclosed |
| EP-0427672-B1 | POLYMER STABILIZERS CONTAINING BOTH HINDERED AMINE AND HYDROXYLAMINE MOIETIES | CIBA-GEIGY AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| WO-1993012158-A1 | METHOD OF PRODUCTION OF POLYMERS AND COPOLYMERS OF CYCLOALKENE OF NORBORNENE TYPE | CHEMOPETROL, S.P. LITVÍNOV VY^´ZKUMNY^´ ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE (CS) | 1993-06-24 | — | — | WO | disclosed |
| US-5202441-A | Heat resistance, photostability | CIBA-GEIGY CORPORATION (US) | 1993-04-13 | — | — | US | disclosed |
| EP-0427672-A1 | Polymer stabilizers containing both hindered amine and hydroxylamine moieties | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | disclosed |
| EP-0413665-A2 | Polymer stabilizers containing both hindered amine and nitrone moieties | CIBA-GEIGY AG (CH) | 1991-02-20 | — | — | EP | disclosed |
| US-4972009-A | PHOTOSTABILIZERS FOR POLYMERS, RADIATION RESISTANCE | CIBA-GEIGY CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
| US-4239891-A | BY REACTING A 4-HYDROXY-4-CYANOPIPERIDINE WITH A TERTIARY ALCOHOL OR AN OLEFIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-12-16 | — | — | US | disclosed |
| EP-0001402-A1 | Substituted piperidinhydroxycarboxylic acid amides, their preparation and their application as light stabilisers | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024525-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | ALDH1A1 1492/4885MEN1 1334/4885MAPK1 3800/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | ALDH1A1 1492/4885MEN1 1334/4885MAPK1 3800/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | ALDH1A1 1492/4885MEN1 1334/4885MAPK1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.